OBJECTIVES: In Sweden, lung transplantation has been performed in patients with end-stage lung disease since 1990. We assessed survival after lung transplantation for cystic fibrosis (CF) with focus on early mortality and outcome for patients infected with certain multiresistant bacteria, considered a relative contraindication for lung transplantation.
INTRODUCTION
Cystic fibrosis (CF) is a hereditary, progressive disease with manifestations in multiple organs and with a shortened life expectancy, mainly due to respiratory failure. In Sweden, a country with 9.8 million inhabitants, CF is a rare disease with less than 700 patients in the whole population and a calculated birth incidence of 1/5600 [1] . The care is centralized to four CF centres.
In Sweden lung transplantation has been a treatment option for end-stage lung disease since 1990. The procedure is performed in Gothenburg and Lund and the first CF patient was transplanted in Nov 1991. Children younger than 15 years of age are transplanted in Gothenburg, and in 2014 a lung transplant program for younger children, previously ineligible for transplantation, was initiated. Currently, there is no Swedish program for living-donor lung transplantation.
In the beginning of the transplant era single lung transplantation was generally performed in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis while double lung transplantation was reserved for CF and pulmonary hypertension. Recently, there has been a shift towards double lung transplantation for all indications [2] . The number of patients assessed for lung transplantation has increased over time and fortunately so has the number of procedures performed. Furthermore, new methods to manage critically ill patients and to optimize lungs from marginal donors have contributed to an increasing number of transplants being performed. Transplantation from a non-heart-beating donor was performed for the first time in history in Lund in 2000 [3] and was followed by in-depth research in ex vivo lung perfusion (EVLP) for reconditioning of explanted lungs, otherwise deemed unsuitable for transplantation [4, 5] . The first reports of extracorporeal membrane oxygenation (ECMO) as a bridge to lung transplantation were discouraging [6, 7] . Lately, acceptable results have been reported for selected patients and the method has been used in Sweden for more than 10 years [8] .
With improved survival and an increasing number of adult patients with CF [9] questions of organ shortage, timing of assessment, transplant selection criteria and management of CFspecific complications after lung transplantation have to be addressed. Multiresistant bacteria pose specific challenges in CF and chronic infection with bacteria belonging to the Burkholderia cepacia complex or Mycobacterium abscessus is considered a significant relative contraindication for lung transplantation [10] . We assessed survival after lung transplantation for CF in Sweden with focus on early mortality and outcome for patients infected with these multiresistant bacteria. We also evaluated if different surgical incision techniques or the use of extracorporeal circulation (ECC)/ECMO during transplantation affected the outcome.
MATERIALS AND METHODS

Patients
All patients who after assessment underwent lung transplantation at the Lund or Gothenburg transplant centres were included in the analysis while a few patients transplanted in England before 1990 were excluded.
Inclusion and exclusion criteria for lung transplantation were kept in accordance with the international guidelines over time [10] . Infection with multiresistant bacteria such as B. cepacia or M. abscessus was not an absolute contraindication for transplantation at our centres.
Demographic and clinical data were extracted from the lung transplant and CF patient databases. Clinical charts were reviewed for details of the perioperative course.
For description of immunosuppression and infection prophylaxis see Table 1 . Patients with B. cepacia complex infection were treated for at least two weeks with combinations of two to three antibiotics. The choice of antibiotics was based on previous clinical effect from treatment. Treatment of M. abscessus has been reported previously [11] .
Ethical considerations
The study was conducted in accordance with the Helsinki declaration. All patients gave informed consent prior to surgery to have their data collected in CF and transplant registries for care management and research purposes.
Statistical methods
The Statistical Package for the Social Sciences, IBM SPSS version 19.0 for Macintosh (IBM Corp., Armonk, NY, USA) was used for all computations. Data are presented as mean (SD) and median (range). The Chi-Square test was used for group comparison and the Kaplan-Meier estimate with log-rank test for survival analysis. A P-value of <0.05 was considered statistical significant.
RESULTS
Overall lung transplant results, all indications
From 1990 to 31 December 2014 a total of 909 transplantations in 847 individuals, including 63 (6.9%) retransplantations were performed in Sweden. There were 485 double lung-, 379 single lung-and 45 heart-lung transplantations. The mean and median age at surgery was 45.1 (SD 14.5) and 49 (range 8-70) years, respectively, for double lung transplant recipients, 54.6 (SD 8.9) and 55 (12-73) years for single lung transplant recipients and 32.4 (SD 13.1) and 32 (7-56) years, respectively, for heart-lung transplant recipients. The overall mean and median waiting time was 185 (SD 230) and 95 (range 1-1865) days, respectively, with the longest waiting time for heart-lung transplantation at a mean of 553 (SD 576) and median of 391 (0-2743) days.
The number of transplantations performed increased over time (Fig. 1) . CF constituted 13% of all lung transplantations in Sweden with 63/301 (21%) procedures in 57 individuals in Lund and 52/608 procedures (8.6%) in 49 individuals in Gothenburg.
Lung transplant results, cystic fibrosis
From November 1991 to December 2014 there were 115 transplantations in 106 CF patients, including nine retransplantations. The mean and median age at surgery was 31 (SD 10) and 30 (range 10-61) years, respectively. Heart-lung transplantation was performed in three patients, double lung in 106, single lung in five, of which four were retransplantations, and double lobar transplantation in one patient. In one patient with severe adhesions after previous lobe resection the decision was made to perform single lung transplantation and leave one native lobe in place. The patient is alive more than 10 years later. Since 2011, five CF patients have received reconditioned lungs, one of them was retransplanted within the first month post-transplant due to graft failure and all were alive by December 2014 with posttransplant follow-up from 5.5 months to 6.5 years. Nine patients were retransplanted at a median of 2.7 years (range 22 days-7.1 years) after the first transplantation due to primary graft loss (2) and bronchiolitis obliterans syndrome (BOS) (7) .
The type of incision varied over time and depended on the surgeon's preference and if ECC was planned or not. Clamshell was the most common incision (60), followed by bilateral sequential thoracotomy (35), sternotomy (16) and unilateral thoracotomy (4). The majority of the procedures 62% (71/115) were performed with ECC or ECMO.
Overall 1-year survival after the first lung transplantation was 86.4%, 5-year survival was 73.7% and 10-year survival was 62.4%. Mean and median survival after the first transplantation was 13.1 (95% CI: 11-15.3) and 14.6 (95% CI: 9.3-19.8) years, respectively (Fig. 2 ). There was no significant difference for transplant centre, gender, if ECC/ECMO was used during surgery (Kaplan-Meier and log-rank test: df = 1, P= 0.174, P= 0.865 and P= 0.187, respectively), or type of incision (df = 2, P= 0.162). Infectious, surgical and vascular complications contributed to eight deaths within the first three postoperative months. The seven deaths which occurred between 3 months and 2 years after surgery were caused by BOS (3), intracranial bleeding (1), diabetic coma (1), Epstein-Barr virus-related post-transplant lymphoproliferative disease (1) and surgical and infectious complications (1) ( Table 2 ). The pretransplant bacteria listed in Table 2 contributed substantially to the post-transplant infections. Two critically ill patients died the first day due to sepsis and multiorgan failure. One woman was operated while on ECMO after severe and rapid deterioration during early pregnancy requiring hysterectomy for termination of the pregnancy. Another woman was transplanted almost 20 years ago, before ECMO was available and was in serious condition already when listed. One woman was postoperatively diagnosed with severe venous occlusions and suffered anoxic brain damage. Thoracic computed tomography performed at assessment may not have captured the diagnosis or the patient may have contracted new occlusions during the 2-year waiting time prior to transplantation. Two patients died from invasive Aspergillus fumigatus infection during the second month. One was a 28-year-old man with severe postoperative complications including reoperation for bleeding, rejection and Pseudomonas aeruginosa airway infection followed by pericardial effusion requiring drainage. A. fumigatus was cultured from the pericardial fluid and from the blood and he died from disseminated A. fumigatus infection and multiorgan failure. Sputum cultures had been negative for A. fumigatus during the three years preoperatively. The other patient was a 38-year-old woman who had been treated for A. fumigatus bronchitis one year earlier but had had negative fungal sputum cultures since treatment. Fungal hyphae were detected in bronchial wash from the anastomoses and A. fumigatus was confirmed in cultures. Despite treatment with inhaled amphotericin B and oral voriconazol she died from massive bleeding caused by necrosis in the anastomotic area. Postmortem biopsy confirmed extensive fungal infection in the lungs and bronchi. No signs of fungal infection were described in the examination of the native lungs for either patient.
ECMO was used as a bridge to transplantation for 11 patients, one of whom died waiting. Two died after 1.4 and 10 years, respectively, and seven were still alive one to 9.6 years after surgery (Table 3) .
Lung-transplant results, cystic fibrosis and multiresistant bacteria
We assessed the impact of preoperative infection with certain multiresistant bacteria considered as a significant relative contraindication for lung transplantation. There were four patients with chronic M. abscessus infection and 10 with B. cepacia complex infection: Burkholderia vietnamensis (3), Burkholderia cenocepacia (2) and Burkholderia multivorans (5). The patients with M. abscessus infection have previously been reported [11] . In December 2014 one patient had died, five years after surgery, the cause of death not being related to lung function or M. abscessus infection. Three patients were alive up to 12 years after surgery. In the B. cepacia complex group there were three deaths; one man colonized with B. vietnamensis pretransplant died after 17 months from chronic rejection and one woman colonized with B. multivorans died after 2 months from infectious complications. Finally, one teenager colonized with B. cenocepacia died after almost 4 years from chronic rejection and infection. However, there was an issue of compliance in this case. One woman colonized with B. vietnamensis underwent retransplantation after 2 years and is alive 5 years later. Using Kaplan-Meier and the log-rank test, patient survival was not shown to be worse in patients harbouring these multiresistant bacteria compared to the rest of the CF group (df 1, P = 0.97) (Fig. 3) . The mean survival in patients harbouring M. abscessus or B. cepacia was 8.8 years (95% confidence interval (CI): 6.1-11.6) compared to 13.2 years (95% CI: 10.9-15.8) in patients free from these bacteria. The observation time was shorter in patients harbouring M. abscessus or B. cepacia with the first patient transplanted in 1998. When excluding 20 patients transplanted before 1998 from the analysis the mean survival was 11 years (95% CI: 9.2-12.8) and there was still no difference between the groups (P = 0.95). As there were few patients in the multiresistant group, statistical comparisons should be interpreted with care.
Waiting list results, cystic fibrosis
The mean and median waiting time was 258 (SD 331) days and 136 days (range 1 day-5 years), respectively, and 80% of the listed patients underwent transplantation within 1 year (retransplantations included). Nineteen CF patients (14% of all CF listed) died while on the waiting list at a median age of 28 (range 6-47) years and a median waiting time of 94 days (range 4 days-2.5 years) after listing, three while waiting for retransplantation. As double lung transplantation is the preferred procedure for all diagnoses we assessed if the waiting time had changed over time in CF. When comparing the last 10 years with previous years the median waiting time for double lung transplantation had decreased from 136 (range 0-1865) days up to December 2004 compared to 64 (0-1638) days after Jan 2005.
DISCUSSION
In this study we report the Swedish experience of lung transplantation for CF regarding survival, cause of mortality within 2 years after surgery as well as outcome in patients with pretransplant colonization with M. abscessus or B. cepacia complex species.
Overall survival in CF has improved and children born with CF today have a better prognosis than the previous generation, with an expected median survival of 40-50 years [12] and with prospects of further improvement due to research in areas such as gene therapy and targeted correctors and modifiers of the CF transmembrane conductance regulator channel function. As CF is still a severe, progressive disease with a median age at lung transplantation of about 30 years [13, 14] , these young individuals will have to cope with transition to adult CF care, as well as all the normal issues in adolescence, at the time of severe deterioration.
The mean age at transplantation in CF is considerably lower than the increasing overall mean age at lung transplantation, currently at 55 years (2013), with the majority of recipients having idiopathic pulmonary fibrosis or chronic obstructive pulmonary disease [13] . In our opinion, the question of lung transplantation should be discussed early with the young CF patient with deteriorating health, addressed repeatedly, and assessed well before the patient becomes severely ill. Nevertheless, the transplant decision and listing may be postponed if the patient is stabilized or not psychologically ready for listing. Heart-lung transplantation was performed in the early transplant era in two of our CF patients with significant pulmonary hypertension. Today we would have opted for double lung transplantation instead. The third heart-lung transplantation in our series was a man with heart failure. During lung transplant assessment he was diagnosed with cardiomyopathy unrelated to CF. Ischemic heart disease is uncommon in CF patients and probably due to these patients' younger age and fewer risk factors, such as smoking and metabolic syndrome, compared to the general population. With an anticipated increasing future mean age at transplantation for CF the need to assess for heart disease will become more important. Obesity, with the concurrent risk of cardiovascular disease, has been described in CF patients [15, 16] and pancreatic insufficient patients with a long history of CFrelated diabetes may also be at risk. Persistent tachycardia, due to severe lung disease, hypoxia and drug side effects from inhalation therapy may lead to heart failure but with adequate treatment the myocardial function may improve, exemplified by one of our patients who was initially discussed for heart-lung transplantation but who improved after treatment with beta-blocker and angiotensin converting enzyme inhibitor.
Several recent publications have discussed EVLP, as well as increasing the donor pool by use of marginal donors and donation after circulatory death. The results of transplantation from marginal donors are generally good. It has been suggested that, in order to further improve the overall outcome, the marginal donors should be matched with low risk recipients [17] [18] [19] [20] but this may be difficult to accomplish except at large transplant centres. This study's primary outcome was patient survival, as opposed to graft survival. Two patients with early graft failure required ECMO while waiting for retransplantation and both have been doing well thereafter. ECMO is, however, not an option for all waiting patients and organ shortage and death on the waiting list are a threat to all listed patients. In children and small patients, lobar transplantation is an option to overcome the limited number of donor organs for this group [21] . We found that despite an increased number of transplantations and a shift from single-to double lung transplantation in all indications the waiting time for CF had decreased during the last 10 years at our centres. An increased donor-pool, use of marginal donors and timely listing have all contributed to the result.
Chronic lung allograft dysfunction (CLAD), a major risk factor for survival, was the main cause of death from 3 months to 2 years after transplantation. CLAD, with obstructive functional limitation, was also the indication in all cases of retransplantation, except for two early graft failures.
Infectious complications contributed to nine deaths within the first 2 years postoperatively. In CF the upper airway infection may exist as a reservoir for post-transplant lung infection. The infection in the native lungs, thoracic cavity and lymph nodes may also contaminate the donor lungs during surgery. It is thus important to choose an effective combination of antibiotics, mode of delivery and duration of treatment, preferentially planned preoperatively and adjusted according to surgical findings and clinical course. In the majority of cases, the pretransplant colonizing bacteria are cultured from sputum or broncho-alveolar lavage during the first year after transplantation (abstract Hansson ECFC, 2014 and unpublished data Gothenburg).
Intermittent airway colonization with A. fumigatus is common in CF and is not a contraindication for lung transplantation but colonization preoperatively should prompt prophylactic treatment postoperatively. One of our early patients, with negative fungal cultures preoperatively, probably contracted the fungal infection from contaminated areas within the surgical and intensive care units during a rebuilding of the hospital. The other patient had negative cultures preoperatively but had a history of previous infection and there was likely still a low-grade colonization at the time for surgery. She may also have contracted the infection from the donor or the surrounding area although this seems less likely.
Few patients harboured B. cepacia complex or M. abscessus and thus we chose to group them together in the survival analysis. The data have to be interpreted with caution but we consider the results encouraging enough to continue transplanting these patients. From the patient s perspective the chance of longterm survival is better with lung transplantation than without. The patient should however be carefully informed of the increased risk of post-transplant complications. Treatment with prolonged antibiotics involves numerous possible side effects and there is a high risk of abscesses in skin, bone and the transplanted organ from M. abscessus, and pulmonary infection and sepsis from B. cepacia complex. The M. abscessus strains were not subtyped, which may be of importance as there are indications of better response to antibiotic treatment for M. massiliense compared to M. abscessus [22] . Only two patients were infected with B. cenocepacia, the species with the highest risk of mortality [10] .
Offering transplantation to critically ill patients and to patients with contraindications will convey the risk of impaired results. Even if long-term results after lung transplantation have improved, the procedure cannot be considered as a cure for CF, as recently suggested [23] , but hopefully as a good long-lasting palliation with few and manageable long-term complications. Stretching the limits, it will also offer a possibility of long-term survival for patients with medical issues, currently considered as contraindications for transplantation.
We conclude that survival after lung transplantation in Sweden is good, also for patients with pretransplant infection with M. abscessus or B. cepacia complex, and comparable to international data.
